Bobby Sandage, entrepreneur, is the guest on this episode of the AEGIS Podcast.
Bobby is currently President and CEO of Euclises. He is Chairman of the board of Immunophotonics and a member of the board of directors of EDIS. He is also a member of the Cultivation Capital life sciences fund investment committee and a member of the Selection Committee of iSelect Fund (www.iselectfund.com).
Bobby was formerly President and CEO of Coronado Biosciences. Before that, he was VP of Embedded Therapeutics at Covidien Pharmaceuticals. Earlier, he was executive vice president of research and development and chief scientific officer at Indevus Pharmaceuticals. He also held senior drug development positions within the cardiovascular research and development division of DuPont Merck Pharmaceutical Company and with the medical department of DuPont Critical Care.
Bobby is an adjunct professor in the department of pharmaceutical sciences at the Southern Illinois University at Edwardsville School of Pharmacy. He received his Ph.D. in clinical pharmacy from Purdue University and his B.S. in pharmacy from the University of Arkansas.
Strategic Engagement
Consult with our Managing Partner.
Ready to review your enterprise risk or legacy strategy? Schedule a direct consultation with Scott Levine using the link below.
